Coronary heart disease (CHD) is a major global health problem, especially among people with type 2 diabetes. Researchers at the German Center for Diabetes Research (DZD), Helmholtz Munich, and Ludwig-Maximilians-University Munich (LMU) have identified novel protein biomarkers that are associated with the development of CHD in people with and without diabetes.
Coronary heart disease is one of the most common causes of death worldwide, especially in Europe where it is responsible for nearly half of all deaths. Among middle-aged adults, individuals with type 2 diabetes (T2D) have a two to four times higher risk of developing CHD than people without T2D. The research team investigated the predictive performance of protein biomarkers on incident CHD in individuals with and without T2D.
For their study, published in Cardiovascular Diabetology, the researchers used data from Cooperative Health Research in the Region of Augsburg (KORA). The validation cohort included 888 participants from the KORA-Age1 study with 70 incident cases of CHD (19 vs. 51 cases in the group with T2D and without T2D, respectively) during 6.9 years of follow-up. They tested blood samples of the subjects for 233 plasma proteins related to cardiovascular disease and inflammation.
The researchers thus identified two proteins associated with incident CHD in individuals with diabetes and 29 proteins in those without baseline T2D. Six of these proteins are novel candidates for incident CHD.
The results of this study contribute significantly to a better understanding of the pathophysiology of CHD in T2D patients and offer potential new approaches to the prevention and treatment of this serious complication. They underscore the importance of further research in this area and the role of the German Center for Diabetes Research in resolving pressing issues related to diabetes and its complications.
- Luo H, Huemer MT, Petrera A et al. Association of plasma proteomics with incident coronary heart disease in individuals with and without type 2 diabetes: results from the population-based KORA study. Cardiovasc Diabetol. 2024 Feb 3; 23 (1): 53. doi:10.1186/s12933-024-02143-z